Xencor EV/EBIT XNCR

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2016.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 27.6×; Feb 2023
10-year median: 38.5×
10-year range: 10.1× to 96.3×
Peer median: 10.0×

Xencor has no meaningful EV/EBIT today: it made an operating loss of $216.1M over the last twelve months.

It was last meaningful in Feb 2023, at 27.6×.

On the days it had one over the last ten years, its median was 38.5×, from 10.1× in Jun 2022 to 96.3× in Feb 2020.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	27.6×	20.5×	32.0×
2022	19.4×	10.1×	35.7×
2021	n/m a value too high to mean anything
2020	78.1×	59.6×	96.3×
2019	63.1×	37.8×	76.9×
2018	n/m a value too high to mean anything
2017	68.5×	19.7×	74.0×
2016	24.5×	17.3×	25.6×

Against its peers

Companies in Drug Manufacturers - General nearest Xencor's size, closest first, today.

Company	EV/EBIT
XNCRXencor	n/m
ANIPANI Pharmaceuticals	10.5×
HRMYHarmony Biosciences	6.9×
PAHCPhibro Animal Health	11.7×
PBHPrestige Consumer Healthcare	14.5×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	7.6×
NRIXNurix Therapeutics	7.1×
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	12.2×
OGNOrganon	9.5×
Peer median	10.0×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Xencor

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.